Fresenius Kabi has announced a nationwide recall of Tyenne® (tocilizumab‑aazg) 400 mg/20 mL vials.

The recall was initiated after detection of glass particles in the vials, prompting safety concerns.

This notice includes detailed product information, distribution scope, and recommended actions tailored for healthcare providers and facilities to ensure patient safety.

Healthcare professionals are advised to review existing inventories and follow recall instructions carefully.